Tailored Rabbit Antithymocyte Globulin Induction Dosing for Kidney Transplantation

Area of Science:

• Nephrology
• Immunology
• Transplant Surgery

Background:

• Rabbit antithymocyte globulin (rATG) is a primary induction immunotherapy for kidney transplants in the US.
• Current FDA-approved dosing involves 1.5 mg/kg daily for up to 7 days via a central line.

Purpose of the Study:

• To evaluate the safety and efficacy of a reduced, risk-stratified dosing protocol for rATG in kidney transplant recipients.
• To compare outcomes of reduced rATG dosing with conventional regimens.

Main Methods:

• Retrospective analysis of 224 adult kidney transplants (2008-2013).
• Risk-stratified rATG dosing: 3 mg/kg (low risk, living donor), 4.5 mg/kg (low risk, deceased donor), 6 mg/kg (high immunologic risk).
• Peripheral administration was utilized for lower-dose groups.

Main Results:

• No significant differences in patient or graft survival across dosing groups.
• One-year rejection rates were comparable to national benchmarks (8.3% and 8.8%).
• Significant cost savings (US $1,091,502), reduced length of stay (by ~3 days), no phlebitis, and comparable infection rates.

Conclusions:

• Reduced, peripherally administered rATG dosing is safe and effective for kidney transplantation.
• This strategy achieves excellent allograft outcomes while reducing costs and hospital stay duration.
• Risk-stratification allows tailored immunotherapy, optimizing resource utilization and patient care.